Centuple Global Limited
BSE: CHECKPOINT · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Centuple Global Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Start your research today
Unlock AI insights, financials, peers and live data on Centuple Global Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹12 Cr
TTM · standalone
NET PROFIT
₹0.09 Cr
TTM · standalone
EPS
₹0.19
TTM · standalone
RETURN ON EQUITY
16.7%
TTM · standalone
P/E
216.6x
Q1 FY26 · standalone
EV/EBITDA
254.3x
Q1 FY26 · standalone
EBITDA MARGIN
0.9%
TTM · standalone
NET PROFIT MARGIN
0.2%
Q4 FY26 · standalone
DEBT TO EQUITY
3.3x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Centuple Global LimitedCHECKPOINT | ₹20 Cr | 216.58 | 182.64 | 1075.7% | 0.9% | 16.7% | 19.6% | +23.9% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q1 FY26
Financials
Centuple Global Limited
BSE: CHECKPOINT · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Centuple Global Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Start your research today
Unlock AI insights, financials, peers and live data on Centuple Global Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹12 Cr
TTM · standalone
NET PROFIT
₹0.09 Cr
TTM · standalone
EPS
₹0.19
TTM · standalone
RETURN ON EQUITY
16.7%
TTM · standalone
P/E
216.6x
Q1 FY26 · standalone
EV/EBITDA
254.3x
Q1 FY26 · standalone
EBITDA MARGIN
0.9%
TTM · standalone
NET PROFIT MARGIN
0.2%
Q4 FY26 · standalone
DEBT TO EQUITY
3.3x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q1 FY26